Extraction chromatography–electrodeposition(EC–ED) process to recover palladium from high-level liquid waste

The extraction chromatography–electrodeposition(EC–ED) process was proposed for the quantitative recovery of palladium from high-level liquid waste(HLLW) in this study. The process coupled the extraction chromatography method to obtain the decontamination of Pd(II) from HLLW with the electrochemical method to recover metallic palladium from the concentrated solution.Separation of Pd(II) from a nitric acid medium by extraction chromatography using iso Bu-BTP/SiO_2-P adsorbent and the electrochemical behavior of Pd(II) in nitric acid solution in the presence of thiourea(TU) were investigated.iso Bu-BTP/SiO_2-P exhibited a high selectivity for Pd(II)over other fission products(FPs), and Pd(II) could be desorbed by TU from loaded BTP/SiO_2-P. The adsorbent performed good stability against HNO_3 because the adsorption performance kept Pd(II) after extended contact with HNO_3 solution. The column experiment achieved the separation of Pd(II) from simulated HLLW successfully.The electrochemical behavior of Pd(II) in palladium desorption solution containing TU and nitric acid was investigated at a platinum electrode by cyclic voltammetry. A weak reduction wave at-0.4 V was due to the reduction in Pd(II) to Pd(0), and the deposition process wasirreversible. In electrowinning experiments, a maximum of92% palladium could be obtained.

Consensus on safety management of novel hormonal therapy for advanced prostate cancer

Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality rates.Novel hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable clinical benefits.However,the diverse range of adverse events(AEs)associated with NHT may influence both treatment efficacy and patients'quality of life.In light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines,this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa patients.Additionally,it seeks to develop a hierarchical approach to more efficiently manage AEs,presenting valuable insights for clinical medication and adverse reaction management.

Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer,one year follow-up

Objective： In the present study, we have examined the safety and efficacy of recombinant adenovirus encoding human p53 tumor suppressor gene （rAd-p53） injection in patients with advanced non-small-cell lung cancer （NSCLC） in the combination with the therapy of bronchial arterial infusion （BAI）. Methods： A total of 58 patients with advanced NSCLC were enrolled in a non-randomized, two-armed clinical trial. Of which, 19 received a combination treatment of BAI and rAd-p53 （the combo group）, while the remaining 39 were treated with only BAI （the control group）. Patients were followed up for 12 months, with safety and local response evaluated by the National Cancer lnstitute＇s Common Toxicity Criteria and response evaluation criteria in solid tumor （RECIST）, respectively. Time to progression （TTP） and survival rates were also analyzed by Kaplan-Meier method. Results In the combo group, 19 patients received a total of 49 injections ofrAd-p53 and 46 times of BAI, respectively, while 39 patients in the control group received a total of 113 times of BAI. The combination treatment was found to have less adverse events such as anorexia, nausea and emesis, pain, and leucopenia （P〈0.05） but more arthralgia, fever, influenza-like symptom, and myalgia （P〈0.05）, compared with the control group. The overall response rates （complete response （CR）＋partial response （PR）） were 47.3% and 38.4% for the combo group and the control group, respectively （P〉0.05）. Patients in the combo group had a longer TTP than those in the control group （a median 7.75 vs 5.5 months, P-0.018）. However, the combination treatment did not lead to better survival, with survival rates at 3, 6, and 12 months in the combo group being 94.74%, 89.47%, and 52.63%, respectively, com- pared with 92.31%, 69.23%, and 38.83% in the control group （P=0.224）. Conclusion： Our results show that the combination of rAd-p53 and BAI was well tolerated in patients with NSCLC and may have improved the quality of life and delayed the disease progression. A further study to better determine the efficacy of this combination therapy is warranted.

Adsorption behavior of Me2-CA-BTP/SiO2-P adsorbent toward MA(Ⅲ) and Ln(Ⅲ) in nitrate solution

A porous Me2-CA-BTP/SiO2-P adsorbent was prepared to separate MA（III） from Ln（III） in high level liquid waste （HLLW）. The adsorption behavior of Me2-CA-BTP/SiO2-P toward 241Am（III） and Ln（III） in 0.01 M HNO3-NaNO3 solution was studied. Me2-CA-BTP/SiO2-P showed high adsorption and selectivity toward 241Am（III） over Ln（III） fission products with the separation factor （SF） reaching to 557, 2355, 1952, 1082, 214, 105, 86, 14 for Y, La, Ce, Nd, Sm, Eu, Gd and Dy respectively in 0.01 M HNO3-0.99 M NaNO3 solution. The adsorption kinetics of both Dy（III） and Eu（III） on Me2-CA-BTP/SiO2-P was studied and followed pseudo-second-order rate equation indicating chemical sorption as the rate-limiting step of the adsorption, and the adsorption isotherm of Dy（III） and Eu（III） matched better with the Langmuir isotherm than the Freundlich isotherm with the adsorption amount around 0.22 and 0.20 mmol/g respectively. Thermodynamic study revealed that the adsorption of both Dy（III） and Eu（III） on Me2-CA-BTP/SiO2-P was spontaneous and endothermic processes with a positive entropy at 298, 308, 313 K.